Cosmo Pharmaceuticals Statistics

Total Valuation

Cosmo Pharmaceuticals has a market cap or net worth of EUR 1.11 billion. The enterprise value is 981.61 million.

Market Cap	1.11B
Enterprise Value	981.61M

Important Dates

The next estimated earnings date is Thursday, March 6, 2025.

Earnings Date	Mar 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.77%
Shares Change (QoQ)	+0.54%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	8.42M

Valuation Ratios

The trailing PE ratio is 15.94.

PE Ratio	15.94
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	11.09
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.57, with an EV/FCF ratio of 8.61.

EV / Earnings	14.11
EV / Sales	5.20
EV / EBITDA	9.57
EV / EBIT	11.20
EV / FCF	8.61

Financial Position

The company has a current ratio of 4.85, with a Debt / Equity ratio of 0.00.

Current Ratio	4.85
Quick Ratio	4.35
Debt / Equity	0.00
Debt / EBITDA	0.01
Debt / FCF	0.01
Interest Coverage	21.40

Financial Efficiency

Return on equity (ROE) is 14.80% and return on invested capital (ROIC) is 9.59%.

Return on Equity (ROE)	14.80%
Return on Assets (ROA)	7.82%
Return on Capital (ROIC)	9.59%
Revenue Per Employee	546,773
Profits Per Employee	205,230
Employee Count	325
Asset Turnover	0.27
Inventory Turnover	3.19

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +3.82% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+3.82%
50-Day Moving Average	66.32
200-Day Moving Average	72.91
Relative Strength Index (RSI)	58.12
Average Volume (20 Days)	4

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cosmo Pharmaceuticals had revenue of EUR 185.36 million and earned 69.57 million in profits. Earnings per share was 4.32.

Revenue	185.36M
Gross Profit	141.74M
Operating Income	85.98M
Pretax Income	86.61M
Net Income	69.57M
EBITDA	99.91M
EBIT	85.98M
Earnings Per Share (EPS)	4.32

Full Income Statement

Balance Sheet

The company has 133.41 million in cash and 1.46 million in debt, giving a net cash position of 131.96 million.

Cash & Cash Equivalents	133.41M
Total Debt	1.46M
Net Cash	131.96M
Net Cash Per Share	n/a
Equity (Book Value)	505.39M
Book Value Per Share	31.06
Working Capital	145.72M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 117.33 million and capital expenditures -3.34 million, giving a free cash flow of 113.99 million.

Operating Cash Flow	117.33M
Capital Expenditures	-3.34M
Free Cash Flow	113.99M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 76.47%, with operating and profit margins of 46.38% and 37.53%.

Gross Margin	76.47%
Operating Margin	46.38%
Pretax Margin	46.72%
Profit Margin	37.53%
EBITDA Margin	53.90%
EBIT Margin	46.38%
FCF Margin	61.50%

Dividends & Yields

Cosmo Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	2
Payout Ratio	6.07%
Buyback Yield	0.77%
Shareholder Yield	0.77%
Earnings Yield	6.27%
FCF Yield	10.28%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Cosmo Pharmaceuticals has an Altman Z-Score of 5.97.

Altman Z-Score	5.97
Piotroski F-Score	n/a